Solos Endoscopy, a HealthCare instrument company, has announced its plans to expand its MammoView Breast Endoscopy product line and also intends to market its product, MammoView breast endoscopy components to the hospitals both in local and international markets via direct sales channels.
The MammoView Breast Endoscopy product line includes six novel breast endoscopy components. Solos Endoscopy’s President, Bob Segersten said that the company is upgrading its MammoView breast endoscopy product line by developing innovative instruments including a new biopsy device to support its existing line, and is also working on acquiring the necessary regulatory approvals to expand its market base.
Solos Endoscopy instruments are approved by FDA. The company will soon be able to apply the CE Mark on all its products upon the receipt of ISO 13485 certification. This move will allow the company to market the MammoView breast endoscopy components across the world.
The MammoView breast endoscopy system features advanced microendoscopes along with optical technology to provide physicians with clear and sharp images of the milk ducts, in which majority of breast cancers develop. Using advanced tissue preservation techniques and minimally invasive technologies, Solos' intraductal devices ensure direct observation with any type of endoscopic video system and provide unprecedented image quality.
The MammoView instrument line is exclusively modeled for breast endoscopy and has become essential for screening breast cancer to significantly reduce death rates. The Solos MammoView breast endoscopy system can identify and distinguish pre-cancerous lesions, which are impossible to detect using other methods, and also supports current diagnosis and treatment methods with direct endoscopic observation.
Source: http://www.solosendoscopy.com